This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?
by Zacks Equity Research
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of 9.09% and 2.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 52.63% and 52.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of -16.67% and 2.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
by Zacks Equity Research
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of -11.11% and 2.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -50% and 12.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Xeris (XERS) Might Surprise This Earnings Season
by Zacks Equity Research
Xeris (XERS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza
by Zacks Equity Research
Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.
Taro Pharmaceutical (TARO) Tops Q2 Earnings Estimates
by Zacks Equity Research
Taro (TARO) delivered earnings and revenue surprises of 111.11% and 8.03%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Ironwood (IRWD) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Ironwood (IRWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 6.90% and 3.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -14.81% and 4.62%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Xeris (XERS), Horizon to Develop Ready-to-Use Teprotumumab
by Zacks Equity Research
Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.
Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 1.69% and 97.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyell Immunopharma (LYEL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Lyell Immunopharma (LYEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lannett (LCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lannett (LCI) delivered earnings and revenue surprises of 8.70% and 10.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma (XERS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -11.68% and 11.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma (XERS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 0% and 66.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 34.44% and 93.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?